Human IL-17/IL-17A Antibody

Catalog #: MAB31711 Datasheet

Catalog #	Availability	Size / Price	Qty
MAB31711-100
MAB31711-SP

IL-6 Secretion Induced by IL-17A/F Heterodimer and Neutralization by Human IL-17A Antibody.

1 Image

All IL-17/IL-17A Antibodies

Product Details

FAQs

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human IL-17/IL-17A Antibody Summary

Species Reactivity

Human

Specificity

Detects human IL-17A and human IL-17A/IL-17F heterodimer in direct ELISAs.

Source

Monoclonal Mouse IgG_2A Clone # 1019404

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Chinese Hamster Ovary cell line CHO-derived
Human IL17A
(Gly24Ala155)
Accession # Q16552
Human IL17F
(Arg31Gln163)
Accession # Q96PD4

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Neutralization

Measured by its ability to neutralize IL‑17A/F heterodimer-induced IL‑6 secretion in the NIH-3T3 mouse embryonic fibroblast cell line. The Neutralization Dose (ND₅₀) is typically 1-6 µg/mL in the presence of 10 ng/mL Recombinant Human IL‑17A/F Heterodimer and 0.5 ng/mL Recombinant Mouse TNF- alpha.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

IL-6 Secretion Induced by IL-17A/F Heterodimer and Neutralization by Human IL-17A Antibody. Recombinant Human IL-17A/F Heterodimer (5837-IL), the the presence of Recombinant Mouse TNF-alpha (0.5 ng/mL, 410-MT), stimulates IL-6 secretion in the NIH-3T3 mouse embryonic fibroblast cell line in a dose-dependent manner (orange line), as measured by the Mouse IL-6 Quantikine ELISA Kit (M6000B). IL-6 secretion elicited by Recombinant Human IL-17A/F Heterodimer (10 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IL-17A Monoclonal Antibody (Catalog # MAB31711). The ND₅₀ is typically 1-6 μg/mL.

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-17/IL-17A

Human IL-17A/F is an approximately 40 kDa, secreted, disulfide-linked heterodimeric glycoprotein comprised of two members of the IL-17 family of cytokines, IL-17A and IL-17F (1, 2). Members of this family demonstrate a structural motif termed a cysteine knot that also characterizes a large superfamily of growth factors. Although most cysteine knot superfamily members use three intrachain disulfide bonds to create a knot, IL-17 family molecules generate the same structural form with only two disulfide links (3-5). Mature human IL-17A and IL-17F share 61% and 56% amino acid sequence identity with mouse IL-17A and IL-17F, respectively. They share 50% aa sequence identity with each other. IL-17A/F and the IL-17A and IL-17F homodimers are produced by IL-23 activated Th17 cells (1, 6-10). The widely expressed receptors IL-17 RA and IL-17 RC form a heterodimer for the binding of IL-17A and IL-17F, as well as the heterodimeric IL-17A/F (6, 11, 12). IL-17A/F is a biologically active protein that induces chemokine production and airway neutrophilia with intermediate potency between IL-17A (most potent) and IL-17F (least potent) (7, 12). It is up-regulated in immune cells during inflammatory arthritis and contributes to disease severity (13).

References

Wright, J.F. et al. (2007) J. Biol. Chem. 282:13447.
Chang, S.H. and C. Dong (2007) Cell Res. 17:435.
Kawaguchi, M. et al. (2004) J. Allergy Clin. Immunol. 114:1265.
Kolls, J.K. and A. Linden (2004) Immunity 21:467.
Gu, C. et al. (2013) Cytokine 64:477.
Cheung, P.F.Y. et al. (2008) J. Immunol. 180:5625.
Liang, S.C. et al. (2007) J. Immunol. 179:7791.
Ouyang, W. et al. (2008) Immunity 28:454.
Steinman, L. (2007) Nat. Med. 13:139.
Hunter, C.A. (2005) Nat. Rev. Immunol. 5:521.
Kuestner, R.E. et al. (2007) J. Immunol. 179:5462.
Wright, J.F. et al. (2008) J. Immunol. 181:2799.
Sarkar, S. et al. (2014) Clin. Exp. Immunol. 177:652.

Long Name

Interleukin 17

Entrez Gene IDs

3605 (Human); 16171 (Mouse); 301289 (Rat); 449530 (Porcine); 481837 (Canine); 102119976 (Cynomolgus Monkey)

Alternate Names

CTLA8; CTLA-8; CTLA8cytotoxic T-lymphocyte-associated serine esterase 8; Cytotoxic T-lymphocyte-associated antigen 8; IL17; IL-17; IL17A; IL-17A; IL-17Acytotoxic T-lymphocyte-associated protein 8; IL-17CTLA-8; IL17interleukin-17A; interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8); interleukin 17A